Abstract
Behavioral heterogeneity within a given patient cohort has been a major challenge in clinical practice and is probably most prominently observed in the field of oncology. This has been the prime impetus of the cutting-edge preclinical and clinical research studies over recent times, many of which seek to further stratify patients based on patients’ genetic, proteomic, and metabolic profile, in order to select the appropriate therapy according to an individual's best-fit. Molecular imaging of breast cancer can potentially be used for breast cancer staging, restaging, response evaluation and guiding therapies. This review focuses on PET imaging which can provide sensitive serial non-invasive information of tumor characteristics. Increasingly, more breast cancer specific targets are imaged such as estrogen receptor (ER) and growth factors. Although molecular imaging of breast cancer is still not commonly used in daily clinical practice, its application portfolio is expanding rapidly.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.